C4 Therapeutics Q3 net loss widens to $32.0M; cash runway to end of 2024

C4 Therapeutics, Inc.

2022-Q3 EPS reported -$1.86 revenue$28,242,000

Net loss $32.0M ($0.65/diluted share) vs $24.7M ($0.51) in Q3 2021; revenue $6.8M vs $8.5M.
Cash, equivalents & marketable securities $366.0M at Sep 30, down from $451.5M at Dec 31, 2021; runway to end of 2024.
Phase 1/2 trials for CFT7455 (IKZF1/3 degrader in MM/NHL) and CFT8634 (BRD9 in synovial sarcoma) advancing dose escalation.
IND clearance for CFT1946 (BRAF-V600 degrader) in Sep; Phase 1/2 to initiate by year-end 2022.
Upcoming milestones: CFT8919 (EGFR L858R) IND-enabling activities to complete by year-end 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

C4 Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.8 million, net income $32.0 million, EPS $0.65.

Period: third quarter ended September 30, 2022
Revenue: $6.8 million
Net income: $32.0 million
EPS: $0.65
Result: reported results

Exact text from the filing

will participate in a fireside chat at the Evercore ISI HealthCONx Conference. THIRD QUARTER 2022 FINANCIAL RESULTS Revenue: Total revenue for the third quarter of 2022 was $6.8 million, compared to $8.5 million for the third quarter of 2021. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.